Sickle Cell Therapy Access in 2026: The Uptake Gap Explained

Introduction: The Gap Between Cure and Access

Since December 2023, people living with sickle cell disease (SCD) have had two FDA-approved gene therapies capable of potentially curing their condition. Casgevy and Lyfgenia were approved on the same day, making them the first cell-based gene therapies ever authorized for SCD. Yet nearly three years later, the number of patients who have actually received these treatments worldwide remains in the low hundreds.

This is the central paradox of sickle cell care in 2026. If Casgevy and Lyfgenia work, why have so few eligible patients started treatment?

The answer has little to do with science and much to do with systems. Three structural forces explain most of the gap:

• Cost and insurance complexity, which requires extensive negotiation before a single patient can be treated
• The state-by-state Medicaid rollout under the CMS Cell and Gene Therapy Access Model
• The scarcity of qualified treatment centers, along with the manufacturing and hospital capacity behind them

The stakes are measured in years of life. A large cohort study estimated life expectancy of approximately 54 years for individuals with SCD, compared with 76 years for those without the disease. For this population, delays in access are not a matter of convenience.

This article connects two stories that are usually told separately. Clinical coverage tends to focus on how these therapies work, while health-equity reporting focuses on who gets them. Understanding the uptake gap requires both perspectives at once.

The Promise: What Casgevy and Lyfgenia Actually Offer

Approximately 100,000 people live with SCD in the United States, and roughly one in every 365 Black or African American newborns in the country is born with the disease. Globally, hundreds of thousands of babies are born with it every year.

Before gene therapy, the only potentially curative option was an allogeneic bone marrow transplant, typically from a matched sibling donor. Many patients simply do not have one. Most care instead focused on management: daily hydroxyurea to reduce pain crises, and chronic blood transfusions, which reduce the risk of first-time stroke by 90% in high-risk children.

Casgevy and Lyfgenia changed that equation by offering a curative path that does not depend on finding a donor. The uptake gap, therefore, is not a question of efficacy. It is a question of access.

Two Mechanisms, One Curative Goal

The two therapies reach a similar outcome through different biological routes:

• Casgevy (exagamglogene autotemcel) is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy. A patient’s own blood stem cells are edited at the erythroid-specific enhancer region of the BCL11A gene. This edit switches back on the production of fetal hemoglobin (HbF), a form of hemoglobin that does not sickle.
• Lyfgenia (lovotibeglogene autotemcel) uses a lentiviral vector to add a functional beta-globin gene to the patient’s stem cells. The modified cells produce a gene-therapy-derived hemoglobin that functions like normal adult hemoglobin.

Both are one-time, single-dose infusions using the patient’s own modified stem cells. This places them in an entirely different treatment category from daily medications or recurring transfusions, and that difference shapes everything about how they are delivered.

Clinical Trial Outcomes: What “Curative” Looks Like

In clinical trials of Casgevy, researchers observed elimination of painful vaso-occlusive crises (VOCs) in more than 90% of patients and complete elimination of VOC-related hospitalizations in all patients. For people whose lives have been organized around unpredictable pain episodes and emergency room visits, those results represent a profound change.

The therapies are not risk-free. The safety profile is generally consistent with autologous stem cell transplantation, which involves intensive conditioning chemotherapy and its associated risks. Still, the outcomes explain the enthusiasm that greeted approval, and they make the slow uptake that followed all the more striking.

The Reality Check: Why So Few Patients Have Started Treatment

Clinical promise and real-world delivery are separate achievements. The most recent commercial data show how wide the distance between them remains.

The Numbers Behind the Headlines

Casgevy generated full-year 2025 revenue of $116 million. During that year:

• 64 patients received Casgevy infusions, including 30 in the fourth quarter alone
• 147 people worldwide with SCD or transfusion-dependent beta thalassemia initiated treatment with their first cell collection

Measured against an eligible population in the tens of thousands, these numbers are small. Only hundreds of patients have entered the treatment pipeline since approval.

It is also important to understand what “initiated” and “infused” mean. The patient journey moves through several stages:

1. Referral to a specialized treatment center
2. Cell collection, in which stem cells are mobilized and harvested
3. Editing or manufacturing, where the cells are modified
4. Conditioning, a chemotherapy regimen that clears space in the bone marrow
5. Infusion of the modified cells

A patient who has “initiated” treatment has completed a first cell collection but may still be months away from infusion. Both milestones matter, and the gap between them reflects the complexity of the process.

Momentum Is Building, But From a Small Base

There is genuine progress. Patient initiations and first cell collections increased nearly three-fold in 2025 compared with 2024, and that momentum has continued into 2026.

Growth percentages, however, can be misleading when the starting point is small. A tripling of a modest number is still a modest number relative to the size of the eligible population. The more useful question is why adoption has been so slow, and the answer lies in a set of interlocking barriers.

Barrier One: The Cost Equation

These therapies rank among the most expensive medical treatments in the world. That scale of expense means coverage is never routine. Before a patient can be treated, insurers, hospitals, and manufacturers must work through financing arrangements that standard drug coverage was never designed to handle.

Traditional fee-for-service payment, in which a payer reimburses a treatment at the time it is delivered, is poorly suited to a one-time therapy whose value accrues over decades. As a result, payers increasingly turn to value-based and outcomes-based contracting.

This financial complexity can add months of administrative lead time to a patient’s journey, independent of whether that patient is clinically ready to begin.

Insurance Negotiation and Outcomes-Based Deals

Outcomes-based agreements tie payment to whether a patient achieves specific clinical benchmarks after infusion, rather than requiring the full cost upfront. If the therapy does not deliver the expected results, the payer may receive rebates or reduced payments.

This structure is designed to manage financial risk for payers. However, it introduces new administrative and data-reporting obligations. Hospitals and payers must track outcomes over time, document results, and coordinate with manufacturers. Each of these steps can slow approval for individual patients.

Barrier Two: The Medicaid Maze and the CMS Cell and Gene Therapy Access Model

If one policy shapes the SCD gene therapy story more than any other, it is Medicaid coverage.

Why Medicaid Coverage Is Central to This Story

Nearly 66% of the U.S. sickle cell population obtains medical coverage through Medicaid, a far higher share than in most disease populations. This means state-level Medicaid policy, not FDA approval alone, effectively determines real-world access for the majority of American patients.

State-by-State Rollout: Who’s In, Who’s Not

The CMS Cell and Gene Therapy Access Model covers Casgevy and Lyfgenia through outcomes-based agreements negotiated at the federal level. Participation, however, is voluntary for each state.

According to the latest available data, 33 states plus Washington, D.C., and Puerto Rico are participating. Together, they represent about 84% of Medicaid beneficiaries with SCD.

That is substantial coverage, but the remaining share matters. A patient’s home state can determine whether Medicaid coverage for these therapies is even an option. Two patients with identical disease severity can face entirely different paths simply because of where they live, creating a geographic lottery that has nothing to do with medical need.

How Outcomes-Based Agreements Work in Practice

In plain terms, these agreements link reimbursement to measurable patient results over time. Instead of a state paying the entire amount at the moment of treatment, payment is connected to whether the therapy continues to work.

The intent is twofold: to manage budget risk for state Medicaid programs and to give manufacturers a direct incentive to ensure durable results. The tradeoff is complexity. States must decide whether to join, build administrative processes, and coordinate with treatment centers, all of which affect rollout timing.

Barrier Three: The Treatment Center Bottleneck

Even when payment is resolved, a patient still needs somewhere to be treated. Physical infrastructure is a second major constraint on uptake.

What It Takes to Become a Qualified Treatment Center

Gene therapy for SCD requires centers capable of:

• Apheresis, the process of collecting stem cells from the blood
• Chemotherapy-based conditioning before infusion
• Extended inpatient monitoring while the new cells engraft

These capabilities closely resemble those of bone marrow transplant centers. Relatively few hospitals nationwide meet these requirements, which creates a structural ceiling on how many patients can be treated at once, regardless of insurance approval.

Geographic Deserts and the Travel Burden

Many eligible patients live far from a qualified center. Because the process can span months, some must relocate temporarily to be near the treatment site.

This burden falls hardest on rural patients and on families with limited financial flexibility. Taking extended time away from work, arranging housing, and stepping back from caregiving responsibilities are obstacles that insurance coverage alone does not solve. The peer-reviewed health-equity literature consistently identifies these socioeconomic factors as central to unequal SCD care.

Capacity Constraints: Manufacturing and Hospital Bandwidth

Analyses from organizations including Milliman have documented barriers such as hospital and manufacturing capacity constraints and long lead times to receive treatment.

The manufacturing challenge is inherent to the therapy. Each patient’s cells must be individually collected, shipped, edited or modified, and returned. This is a personalized process, not mass production. It cannot scale as quickly as a conventional pill or injection, and every step depends on coordination between the hospital and the manufacturer.

Barrier Four: The Patient Journey Itself

Beyond policy and infrastructure, the treatment experience itself presents real operational demands for patients and caregivers.

Long Lead Times From Referral to Infusion

A realistic timeline includes:

• Eligibility screening and clinical evaluation
• Insurance authorization, often involving outcomes-based contract review
• Stem cell mobilization and collection, sometimes requiring more than one cycle
• Manufacturing turnaround
• Conditioning chemotherapy and hospitalization before and after infusion

Taken together, this process often spans many months. For patients managing active pain crises and other complications, the length of the timeline can itself be a deterrent.

Required Supplemental Services

Conditioning chemotherapy can affect fertility, which makes fertility preservation counseling and services an essential, though often overlooked, part of the pathway. Access to these services is unevenly distributed. Coverage varies, and not every treatment center offers them on-site. When these services are delayed or unavailable, the overall treatment timeline can lengthen further.

Who Is Currently Left Out

Both therapies are currently approved only for patients aged 12 and older with severe disease. This excludes younger children, who may benefit most from early intervention before organ damage accumulates.

That boundary is expected to shift. Vertex plans to file for approval of Casgevy in children aged 5 to 11 and has received a Commissioner’s National Priority Review Voucher, which is expected to speed review. A larger eligible population is good news, but without parallel growth in infrastructure, it could widen the access gap before capacity catches up.

The Global Access Gap

The U.S. policy debate, as important as it is, represents only part of the picture.

Approval Footprint vs. Where the Disease Burden Lives

Casgevy is approved in the United States, the European Union, Great Britain, Canada, Switzerland, Saudi Arabia, Bahrain, Qatar, the UAE, and Kuwait for patients 12 and older.

The countries with the heaviest SCD burden are largely absent from that list. Nigeria, India, the Democratic Republic of Congo, and Tanzania carry the greatest disease burden, and about 300,000 babies are born with sickle cell disease every year worldwide. The majority are born in low-income countries, and many will not survive to their fifth birthday.

This makes the uptake gap a global equity issue. A therapy that requires transplant-level infrastructure is, for now, out of reach for most of the people living with the disease.

What’s Coming Next: Could the Pipeline Ease the Bottleneck?

Several near-term developments could reshape the access landscape over the next 12 to 24 months.

Pediatric Expansion for Casgevy

Extending eligibility to children aged 5 to 11 could meaningfully increase demand. Unless treatment center capacity and manufacturing scale in parallel, that added demand will intensify pressure on a system that is already constrained.

Oral Disease-Modifying Alternatives on the Horizon

Two oral therapies are approaching key regulatory milestones:

• Mitapivat (Agios) is under FDA Priority Review with a PDUFA goal date of November 1, 2026. If approved, it would become the first oral pyruvate kinase (PK) activator for SCD.
• Etavopivat (Novo Nordisk) showed a 27% reduction in annualized VOC rate versus placebo in the Phase 3 HIBISCUS trial, with regulatory submission planned for the second half of 2026.

These therapies are not curative. However, they are far less resource-intensive than gene therapy. They do not require apheresis, conditioning chemotherapy, or a specialized center, which makes them much more scalable. For patients who cannot reach a qualified treatment center, oral agents could serve as an important access bridge.

Base Editing as a Potential Differentiator

Beam Therapeutics’ BEAM-101 uses base editing, a technique that changes individual DNA letters without creating the double-stranded DNA breaks used in CRISPR nuclease approaches.

As of mid-2025, the BEACON trial had completed enrollment, with 46 patients initiating mobilization and 26 dosed. No patients had experienced Grade 3 or higher adverse events related to BEAM-101. These are early findings, but they suggest a potentially differentiated safety profile worth watching as the field considers future access and adoption.

A Cautionary Lesson: The Oxbryta Withdrawal

Progress in SCD treatment has not been linear. In September 2024, Pfizer voluntarily withdrew voxelotor (Oxbryta) from all global markets due to severe safety concerns, including fatalities. In October 2025, the European Medicines Agency’s CHMP recommended that its marketing authorization remain suspended after data showed higher mortality with Oxbryta than with placebo.

The episode is a reminder that the treatment landscape continues to evolve, sometimes with setbacks. Patients need current, accurate information rather than outdated treatment lists that may still include withdrawn therapies.

Closing the Gap: What Needs to Change

The four barriers described here reinforce one another:

1. Cost and insurance complexity delays authorization
2. Medicaid state variability makes coverage depend on geography
3. Treatment center scarcity caps how many patients can be treated at once
4. The multi-step patient journey stretches timelines and adds burden

Market momentum is real. The gene-editing therapy segment is projected to grow at roughly a 17.34% compound annual growth rate, reflecting a shift from symptom management toward disease-modifying and potentially curative care. But growth in investment and approvals does not automatically translate into growth in patient access.

Closing the gap will require coordinated action:

• Expanding qualified treatment center networks, particularly in underserved regions
• Achieving full state Medicaid participation in the CMS Access Model
• Streamlining the patient journey, including authorization processes and supplemental services such as fertility preservation
• Supporting patients with practical needs, such as travel, housing, and caregiving, during extended treatment periods

Approving more therapies matters. Building the systems to deliver them matters just as much.

Conclusion

The sickle cell therapy story in 2026 is not a story of insufficient science. It is a story of infrastructure, policy, and access systems working to catch up with scientific capability.

Real progress has been made. Patient initiations nearly tripled year over year, Medicaid participation now reaches a large majority of eligible beneficiaries, and a pediatric label expansion is on the horizon. At the same time, the gap between “approved and curative” and “accessible and realistic” remains wide for most eligible patients, both in the United States and around the world.

The next 12 to 24 months will be decisive. Pipeline approvals, continued Medicaid rollout, and treatment center expansion will determine whether 2026 marks the beginning of meaningful scale-up or a continued plateau.

Next Steps for Patients and Caregivers

For individuals evaluating treatment options for themselves or a loved one, the most important step is a conversation with a hematologist or an accredited sickle cell treatment center. A specialist can help clarify:

• Individual eligibility for gene therapy or other disease-modifying options
• Whether the patient’s state participates in the CMS Cell and Gene Therapy Access Model
• Realistic timelines from referral to treatment, including supplemental services
• The risks and benefits of each option relative to the patient’s specific condition

The landscape is changing quickly. Mitapivat, etavopivat, and BEAM-101 are all approaching important milestones, and available options may look meaningfully different within the year. Staying informed through trusted sources, such as the CDC, the Sickle Cell Disease Association of America, and online resources such as Adiamed, can help families ask better questions.

No single article can replace individualized medical advice. Readers are encouraged to explore further educational resources and to speak with a qualified provider before making any treatment decision.